Alex Hard­ing to chase in­dus­try dreams at CRISPR Ther­a­peu­tics; Scoop: Bio­gen’s head of busi­ness de­vel­op­ment splits for Kite

While Alex Hard­ing is a prac­tic­ing physi­cian, he’s long en­vi­sioned a ca­reer on the busi­ness side of drug de­vel­op­ment. Next year, he’s seiz­ing an op­por­tu­ni­ty to fur­ther those goals at CRISPR Ther­a­peu­tics.

The Swiss-Amer­i­can com­pa­ny an­nounced on Mon­day that Hard­ing — one of End­points News’ 20 un­der 40 hon­orees in 2020 — is join­ing on Jan. 5 as SVP and head of busi­ness de­vel­op­ment. CEO Samarth Kulka­rni said in a news re­lease that the ap­point­ment will be “crit­i­cal in dri­ving the next phase of growth for CRISPR.”

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters